AKBA: Akebia Therapeutics Company Short-Term Debt
Akebia Therapeutics (AKBA) is a biopharmaceutical company specializing in therapies for renal pathologies tailored for pharmacies and dialysis centers. The business model delegates logistical processes to external operators, which is confirmed by the price trend on GURU.Markets, where the metric stands at 0.05. The firm's competitive advantage lies in the development of an oral anemia treatment that replaces injections, simplifying patient daily life and expanding the brand's presence in nephrology.
Summary analytical data breakdowns for Akebia Corp (AKBA)
Short-term debts reflect the total obligations with a maturity of up to one year, determining the issuer's current solvency. Analyzing the dynamics through current loans and borrowings allows for an assessment of liquidity management efficiency. This metric is sensitive to the volume of raised working capital and its servicing rates. For Akebia Therapeutics (AKBA), this indicator is critical during the aggressive rollout of Vafseo into the US market. The increase in borrowings here is justified by scaling the drug's presence in dialysis centers.